Current Progress

Submission received

NMG meeting

AWMSG meeting

Ministerial Ratification

AWMSG advice

Entecavir (Baraclude®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B virus (HBV) infection in nucleoside naive paediatric patients from 2 to < 18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum alanine aminotransferase (ALT) levels, or histological evidence of moderate to severe inflammation and/or fibrosis.